BIOINVEST BREAKING NEWS – Wave’s stock took off after they released the initial INLIGHT data readout for WVE-007 (INHBE siRNA) which ushers in a new player in the obesity landscape. Based on today’s outstanding obesity data, the body “muscle sparing” profile validates INHBE as a novel mechanism of action (MOA) and also de-risks Wave’s RNAi platform. (…more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.